Brentuximab Vedotin (Adcetris)
CD30-directed antibody-drug conjugate for Hodgkin lymphoma and selected T-cell lymphomas.
What is Brentuximab Vedotin?
What it targets
CD30, a protein found on the surface of certain lymphoma cells — the antibody half of the conjugate locks onto CD30 and delivers its chemotherapy payload directly into the cell.
Who it may help
Patients with CD30-positive Hodgkin lymphoma or anaplastic large cell lymphoma, including first-line, post-transplant consolidation, and relapsed or refractory settings.
Why testing matters
CD30 expression must be confirmed by immunohistochemistry before starting treatment; baseline blood counts and liver function are also checked.
Which cancers can Brentuximab Vedotin treat?
Brentuximab vedotin is used across multiple CD30-positive lymphoma types. The specific setting — first-line, post-transplant, or relapsed — depends on the diagnosis and local approval.
| Classical Hodgkin Lymphoma | Used in selected newly diagnosed patients (A+AVD regimen), as post-transplant consolidation in high-risk disease, and in relapsed or refractory CD30-positive Hodgkin lymphoma after prior therapy. |
| Systemic Anaplastic Large Cell Lymphoma (sALCL) | Used in previously untreated sALCL in combination with CHP chemotherapy, and in relapsed or refractory sALCL. CD30 expression is typically very high in this subtype. |
| Peripheral T-cell Lymphoma (PTCL) | Used in selected CD30-expressing PTCL subtypes including AITL and PTCL-NOS in combination with CHP in the first-line setting, subject to local approval and patient suitability. |
| Cutaneous T-cell Lymphoma (CTCL) | Used in CD30-expressing mycosis fungoides or primary cutaneous anaplastic large cell lymphoma after at least one prior systemic therapy, depending on local approval. |
Who may benefit from Brentuximab Vedotin?
Eligibility depends on lymphoma type, CD30 expression, prior treatment history, organ function, and performance status.
- Confirmed CD30-positive lymphoma on immunohistochemistry (IHC) biopsy.
- Diagnosis of classical Hodgkin lymphoma, sALCL, CD30-expressing PTCL, or CTCL.
- Relapsed or refractory disease after prior systemic therapy in eligible settings.
- High-risk Hodgkin lymphoma after autologous stem cell transplant (for consolidation).
- Previously untreated sALCL or selected CD30-positive PTCL (for first-line combinations).
- Adequate blood counts — acceptable neutrophil, hemoglobin, and platelet levels.
- Adequate liver and kidney function as assessed by baseline blood tests.
- No pre-existing severe peripheral neuropathy that would preclude safe treatment.
- Not pregnant; effective contraception required during and after treatment.
How does Brentuximab Vedotin work?
- Step 1 — CD30 targeting
- Step 2 — Internalisation into the cancer cell
- Step 3 — Payload release (MMAE)
- Step 4 — Cancer cell death
Tests needed before starting Brentuximab Vedotin
Your oncologist will request a set of tests to confirm eligibility, establish a baseline, and ensure the treatment is safe to start.
| Biopsy and histopathology | To confirm lymphoma diagnosis and subtype before treatment. |
| CD30 immunohistochemistry (IHC) | Mandatory — confirms CD30 expression on lymphoma cells. Required for eligibility. |
| Complete Blood Count (CBC) | Baseline white cells, hemoglobin, and platelets. Monitored throughout treatment. |
| Liver function tests (LFTs) | Brentuximab vedotin is metabolised hepatically; liver function is checked before and during treatment. |
| Kidney function tests | Assessed for dosing decisions and safety monitoring. |
| PET-CT or CT scan | To stage disease extent and provide a baseline for response assessment. |
| Peripheral neuropathy assessment | Pre-existing neuropathy affects eligibility and monitoring frequency. |
| Pregnancy test | Required for women of childbearing potential before starting treatment. |
| Infection screening | Including hepatitis B testing; relevant given immunosuppressive risk during treatment. |
How is Brentuximab Vedotin given?
Brentuximab vedotin is given as an intravenous (IV) infusion at a hospital or day-care oncology infusion centre. It cannot be taken by mouth or self-administered.
| Standard dose | 1.8 mg/kg given as an IV infusion every 21 days (3-week cycles). |
| Dose in combination regimens | 1.8 mg/kg every 21 days when used with AVD or CHP chemotherapy, subject to oncologist adjustment. |
| Maximum single dose | 180 mg per infusion, regardless of patient weight above 100 kg. |
| Infusion duration | Each infusion is administered over approximately 30 minutes. |
| Setting | Hospital or accredited infusion centre; patients are monitored during and after infusion for reactions. |
| Dose modifications | Dose may be reduced or delayed based on neuropathy severity, blood count recovery, or other side effects. |
| Duration of therapy | Varies by indication — typically 6 to 16 cycles; consolidation after transplant is up to 16 cycles. |
| Missed or delayed infusion | If a cycle is delayed or missed, contact your oncology team promptly. Do not attempt to adjust independently. |
Clinical evidence and potential benefits
Brentuximab vedotin has demonstrated clinical benefit across multiple CD30-positive lymphoma types in landmark clinical trials including ECHELON-1 and ECHELON-2.
| Improved outcomes in Hodgkin lymphoma (ECHELON-1) | In newly diagnosed Stage III/IV Hodgkin lymphoma, A+AVD improved modified progression-free survival compared to ABVD in a large randomised trial. |
| First-line benefit in CD30-positive PTCL (ECHELON-2) | Brentuximab vedotin combined with CHP demonstrated improved progression-free and overall survival compared to standard CHOP in CD30-positive PTCL. |
| Post-transplant consolidation (AETHERA trial) | In high-risk Hodgkin lymphoma after autologous stem cell transplant, brentuximab vedotin consolidation substantially improved progression-free survival versus placebo. |
| Activity in relapsed/refractory Hodgkin lymphoma | Meaningful response rates achieved in heavily pretreated relapsed or refractory Hodgkin lymphoma, including complete responses in a proportion of patients. |
| Activity in relapsed sALCL | High response rates observed in relapsed systemic anaplastic large cell lymphoma, with durable responses in a significant proportion of patients. |
| Targeted delivery reduces off-target toxicity | The CD30-directed mechanism concentrates the cytotoxic payload in lymphoma cells, differentiating it from conventional chemotherapy in its toxicity profile. |
Individual responses vary. These represent published clinical trial data. Results in real-world practice may differ from trial populations.
Side effects of Brentuximab Vedotin
Brentuximab vedotin has a different side effect profile from conventional chemotherapy. Most effects are manageable, but peripheral neuropathy requires close monitoring throughout treatment.
| Peripheral neuropathy | Numbness, tingling, burning, or weakness in hands or feet — one of the most common effects. Report early so dose can be adjusted. |
| Fatigue | Common across all treatment cycles. Rest and pacing activities can help manage daily impact. |
| Nausea and vomiting | Occurs in a proportion of patients; anti-nausea medication is usually provided alongside treatment. |
| Neutropenia (low neutrophil count) | Increases infection risk. G-CSF growth factor support may be used, particularly in combination regimens. |
| Thrombocytopenia (low platelets) | Monitored by CBC; dose delays may be needed if platelet counts fall significantly. |
| Anaemia (low red cells) | Fatigue related to anaemia may be managed with supportive care or transfusion if severe. |
| Diarrhoea or constipation | Gastrointestinal effects are common; dietary adjustment and medication can help manage symptoms. |
| Rash or skin reactions | May include rash, pruritus, or dry skin; usually mild but should be reported if worsening. |
| Fever | May indicate infection or infusion reaction; any fever with low blood counts requires urgent medical review. |
| Infusion-related reactions | Can include chills, flushing, or shortness of breath during or after infusion; managed with premedication in repeat cycles. |
Contact your doctor immediately if you develop:
- Fever with low white blood cell count (febrile neutropenia) — medical emergency.
- Worsening or new numbness, weakness, or pain in hands or feet — may indicate serious neuropathy.
- Breathing difficulty, chest pain, or severe infusion reaction during or after treatment.
- Severe skin reaction, blistering, or peeling rash.
- Signs of progressive neurological changes such as confusion, vision changes, or difficulty walking — rare but serious risk of PML.
- Severe abdominal pain or signs of pancreatitis.
- Yellowing of eyes or skin suggesting liver problems.
Safety precautions and drug interactions
Tell your oncologist and pharmacist about all prescription medicines, over-the-counter drugs, supplements, and herbal products before starting brentuximab vedotin.
- CYP3A4 inhibitors such as ketoconazole or clarithromycin can increase MMAE exposure — dose adjustment may be needed.
- CYP3A4 inducers such as rifampicin can reduce MMAE levels and may reduce treatment effectiveness.
- Bleomycin must not be combined with brentuximab vedotin due to a high risk of severe pulmonary toxicity.
- Pregnancy must be avoided during treatment and for 6 months after the final dose; effective contraception is required.
- Breastfeeding is not recommended during treatment or for at least 3 weeks after the final infusion.
- Pre-existing peripheral neuropathy should be disclosed — affects eligibility and monitoring requirements.
- Live vaccines must not be given during treatment or while the immune system is suppressed.
- Hepatitis B screening is recommended before starting; reactivation can occur in at-risk patients.
- Patients with pre-existing liver disease need closer monitoring during treatment.
Brentuximab Vedotin combination treatments
Brentuximab vedotin is used in several combination regimens depending on lymphoma type and treatment stage. Your oncologist will select the regimen appropriate for your diagnosis.
| A+AVD (Hodgkin lymphoma, first-line) | Brentuximab vedotin combined with doxorubicin, vinblastine, and dacarbazine for Stage III/IV classical Hodgkin lymphoma in the first-line setting. |
| BV+CHP (CD30-positive PTCL, first-line) | Brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone for previously untreated CD30-positive systemic ALCL and selected PTCL subtypes. |
| Post-transplant consolidation (Hodgkin lymphoma) | Used as a single agent after autologous stem cell transplant in high-risk Hodgkin lymphoma to reduce relapse risk. |
| Monotherapy (relapsed/refractory) | Used as a single agent in relapsed or refractory Hodgkin lymphoma or sALCL after failure of prior therapy. |
| Combination with checkpoint inhibitors | Being studied in combination with nivolumab in relapsed Hodgkin lymphoma in clinical trials — not yet standard of care. |
If Brentuximab Vedotin stops working
If lymphoma progresses during or after brentuximab vedotin treatment, several options exist depending on prior therapy and the patient's overall condition.
| Loss of CD30 expression | Rare but possible — repeat biopsy may be considered to reassess CD30 status if disease has transformed. |
| Intrinsic resistance mechanisms | May include drug efflux, reduced drug internalisation, or lysosomal pathway changes that limit MMAE delivery. |
| Salvage chemotherapy options | ICE, DHAP, GDP, or GVD regimens may be used as salvage in relapsed Hodgkin lymphoma prior to transplant consideration. |
| Checkpoint inhibitor immunotherapy | Pembrolizumab and nivolumab are approved for relapsed/refractory classical Hodgkin lymphoma in patients with prior brentuximab vedotin exposure. |
| Allogeneic stem cell transplant | May be considered in eligible patients with relapsed disease following brentuximab vedotin and salvage chemotherapy. |
| CAR-T cell therapy | CD30-targeted CAR-T options and other cellular therapies are being studied in clinical trials for refractory lymphoma. |
| Clinical trial enrolment | Patients with disease refractory to brentuximab vedotin are often eligible for innovative trials in lymphoma-specialised centres. |
Cost of Brentuximab Vedotin by country
Brentuximab vedotin (Adcetris) is a branded biologic with no approved generics. Cost varies significantly by country, dose, number of cycles, and hospital fees.
| India | Adcetris 50 mg is listed through licensed oncology pharmacies; per-cycle costs are substantial. Patients should obtain current pricing through the treating hospital. No local generic is available. CancerFax can assist with cost navigation. |
| China | NMPA-approved Adcetris is available through prescription oncology channels. Pricing varies by hospital and may be partially covered through national insurance schemes for approved indications. |
| USA | Adcetris is very high-cost without insurance. Seagen (now Pfizer) offers a patient assistance programme. Copay support is available for commercially insured patients in approved indications. |
| UK / Europe | Available through NHS and national health systems for approved indications in most EU countries. Funding approval pathways and coverage criteria vary by country. |
| UAE / Gulf | Available through major oncology centres; cost is high and reimbursement varies significantly by insurance plan and country. |
Availability of Brentuximab Vedotin globally
Brentuximab vedotin is available globally as a branded prescription medicine through oncology centres and licensed pharmacies. No approved generics exist as of 2026.
India
Adcetris is available through licensed oncology pharmacies and major cancer centres. Prescription required. No generic version available. Patients should verify current supply and hospital access before planning treatment.
China
NMPA-approved for relapsed/refractory sALCL and CD30-positive Hodgkin lymphoma. Available at major oncology hospitals through prescription channels. Partial national insurance coverage may apply.
USA
FDA-approved for multiple Hodgkin and T-cell lymphoma indications. Available through hospital and specialty pharmacy networks. Patient assistance available through manufacturer.
UK
EMA and MHRA approved. Available through NHS for approved indications subject to NICE/SMC funding guidance. Oncology centres manage access through specialist prescribing pathways.
Germany / EU
EMA-approved. Available through national health systems in EU member states with country-level reimbursement decisions. Available in major academic oncology centres.
Other countries
Available through compassionate use or special import in select countries pending local approval. CancerFax can assist international patients with access checks and coordination.
Brentuximab Vedotin in current clinical trials
Brentuximab vedotin continues to be studied in lymphoma treatment, including new combinations, earlier-line applications, and novel biomarker-selected patient groups.
| Combination with checkpoint inhibitors | Trials exploring brentuximab vedotin combined with nivolumab or pembrolizumab in relapsed Hodgkin lymphoma and transplant-ineligible disease — ongoing in multiple centres. |
| Earlier-line use in T-cell lymphoma | Studies evaluating BV-based regimens in newly diagnosed CD30-low PTCL subtypes to assess whether CD30 threshold guidance should be refined. |
| Paediatric and adolescent lymphoma | Trials examining brentuximab vedotin in paediatric Hodgkin lymphoma including dose optimisation and reduction of long-term toxicity compared to standard regimens. |
| Biomarker refinement studies | Research to identify which CD30 expression levels and genetic features best predict response, with the goal of selecting patients most likely to benefit. |
| Maintenance and sequencing strategies | Studies evaluating extended maintenance after initial response and optimal sequencing with CAR-T or transplant approaches in refractory disease. |
Your treatment journey with Brentuximab Vedotin
Diagnosis and biopsy
Staging and baseline assessment
Oncology consultation and treatment planning
Starting brentuximab vedotin
Ongoing monitoring during treatment
Interim response assessment
End of planned treatment
Post-treatment surveillance
Questions to ask your oncologist about Brentuximab Vedotin
- Is my lymphoma CD30-positive and does that make me eligible?
- Will I receive brentuximab vedotin alone or with chemotherapy?
- How will my neuropathy be monitored and what should I do if it gets worse?
- How many cycles are planned and when will scans be done?
- Can this treatment affect my chances of a stem cell transplant?
- What fertility preservation options are available before I start?
- What is the estimated cost and how can I manage it?
- Are there clinical trials I should know about?
How CancerFax supports Brentuximab Vedotin patients
CancerFax helps lymphoma patients and families understand their treatment options, verify access, and connect with specialist oncologists in India, China, and internationally.
| Medical report review | Upload your biopsy, CD30 IHC result, PET-CT scan, or CBC reports — our team reviews them and explains what they mean for brentuximab vedotin eligibility. |
| Specialist connection | We connect patients with hemato-oncologists experienced in Hodgkin lymphoma, systemic ALCL, and T-cell lymphoma at leading centres in India, China, UAE, and Turkey. |
| Second opinion | If you are unsure about the recommended treatment plan, are not responding to current treatment, or want to explore advanced options, CancerFax arranges specialist second opinions. |
| Cost navigation and access | We help patients check current Adcetris pricing in India and China, and identify patient assistance or access programme options for this medicine. |
| Clinical trial matching | Our team identifies relevant clinical trials for relapsed or refractory lymphoma in India and internationally, including brentuximab vedotin-based combination studies. |
| International treatment coordination | For patients travelling to India or China for treatment, CancerFax coordinates hospital liaison, visa support, interpretation, and logistics. |
Frequently asked questions about Brentuximab Vedotin
Common questions from patients and caregivers about Adcetris treatment
Brentuximab vedotin is not a traditional chemotherapy drug. It is an antibody-drug conjugate — a targeted medicine that carries a chemotherapy-like payload directly into CD30-positive cancer cells. Because it targets CD30 specifically, it is designed to act on lymphoma cells rather than all dividing cells, though side effects such as peripheral neuropathy and low blood counts can still occur.
CD30 is a protein found on the surface of certain lymphoma cells, including Hodgkin lymphoma and some T-cell lymphomas. Brentuximab vedotin contains an antibody that locks onto CD30 and delivers a cell-killing payload inside the cancer cell. If your lymphoma does not express CD30, this drug will not be effective, which is why testing is required before treatment begins.
Response timing varies depending on the lymphoma type, stage, and treatment setting. In clinical studies, many patients showed measurable responses within the first two to three cycles of treatment. Your oncologist will typically assess response with a PET-CT or CT scan after two to four cycles to determine how well the treatment is working.
Peripheral neuropathy is tingling, numbness, burning, or pain in the hands or feet caused by nerve damage. It is one of the most important side effects of bortezomib and can affect quality of life significantly if not managed. Using subcutaneous injection instead of intravenous infusion reduces the risk of neuropathy. Your doctor may reduce the dose, change the schedule, or stop bortezomib if neuropathy becomes severe. Report any new numbness, pain, or difficulty with fine movements promptly — early intervention often prevents worsening.
Yes, in selected high-risk Hodgkin lymphoma patients, brentuximab vedotin is approved as consolidation therapy after autologous stem cell transplant. This approach aims to reduce the risk of disease returning after transplant. Eligibility depends on disease risk features, performance status, and prior treatment history, and should be discussed in detail with your hemato-oncologist.
Brentuximab vedotin can harm an unborn baby and should not be used during pregnancy. Effective contraception is required during treatment and for a period after the final dose, as advised by your oncology team. Breastfeeding is also not recommended during treatment. If you are pregnant or planning to become pregnant, discuss this with your oncologist before starting any treatment.
If lymphoma progresses during or after brentuximab vedotin, your oncologist will likely repeat scans and possibly a biopsy to confirm progression. Options may include salvage chemotherapy, immunotherapy such as checkpoint inhibitors for Hodgkin lymphoma, stem cell transplant, CAR-T cell therapy where available, or enrollment in a clinical trial. A second opinion from a specialist lymphoma centre can be valuable at this stage.
The cost of brentuximab vedotin (Adcetris) varies significantly by country, dose, number of cycles, and hospital charges. In India, Adcetris is listed through licensed oncology pharmacies but the per-cycle cost is substantial; patients should verify current pricing with the treating hospital or oncology pharmacy. In China, NMPA-approved Adcetris is available through prescription oncology channels. CancerFax can assist patients in checking access, cost estimates, and any available patient assistance programmes.